# NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Jun 30, 2017

- Company: [NEUROONE MEDICAL TECHNOLOGIES Corp](/companies/nmtc.md) (CIK 1500198)
- Form: 10-Q
- Filed: 2017-08-14
- Accepted by EDGAR: Aug 14, 2017, 20:53 ET
- Period: 2017-06-30
- Accession: 0001144204-17-043228
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1500198/000114420417043228/v472986_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1500198/000114420417043228/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-04-01 to 2017-06-30 | $0 | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2017-01-01 to 2017-06-30 | $0 | us-gaap:SalesRevenueNet |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | −$23.6k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | −$32.4k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2017-04-01 to 2017-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2017-01-01 to 2017-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | −$23.6k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | −$14.8k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Total assets | at 2017-06-30 | $0 | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $128.5k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $128.5k | us-gaap:Liabilities |
| Shareholders' equity | at 2017-06-30 | −$128.5k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 15,762 characters.

*The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and notes included in Part I “Financial Information”, Item I “Financial Statements” of this Quarterly Report on Form 10-Q and the audited financial statements and related footnotes included in our Annual Report on Form 10-K filed on April 17, 2017.*

### Forward-Looking Statements

Certain statements contained in this Quarterly Report on Form 10-Q are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. We may, in some cases, use words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements.

These forward-looking statements reflect our management’s beliefs and views with respect to future events, are based on estimates and assumptions as of the date of this report and are subject to risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those in these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Any forward-looking statement made by us in this report speaks only as of the date hereof or as of the date specified herein. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable laws or regulations.

### Overview

We were initially incorporated under the laws of the State of Nevada on August 20, 2009 and reincorporated under the laws of Delaware in June 2017. Our business from inception through May 13, 2016 was to license songs to the television and music industry for use in television shows or movies. We have had limited activity and revenue to date and had no assets or operations as of June 30, 2017, since the spin-off of our wholly owned subsidiary, as further described below. As of May 13, 2016, we spun-off Original Source Music, our wholly-owned subsidiary which held all of our operations, to shareholders of record as of February 25, 2014. The spin-off was done in connection with a change of control of our company. Under the terms of the spin-off, Original Source Music’s common shares, par value $0.001 per share, were distributed on a pro-rata basis to each holder of our common shares on the record date without any consideration or action on the part of such holders, and the holders of our common shares as of the record date became owners of 100% of Original Source Music’s common shares, subject to applicable FINRA filings. Accordingly, as of June 30, 2017, we were a blank check registrant as that term is defined in Rule 419(a)(2) of Regulation C of the Securities Act of 1933, because we have no specific business plan and purpose.

Our Board of Directors and our former majority stockholder, who was also our Chief Executive Officer and sole director, authorized, on April 17, 2017:

- An amendment to our Articles of Incorporation to effect a change of our name from “Original Source Entertainment, Inc.” to “NeuroOne Medical Technologies Corporation.”
- An amendment to our Articles of Incorporation to effect an increase in the number of authorized shares of our common stock from 45,000,000 to 100,000,000 and to increase the number of authorized shares of our preferred stock from 5,000,000 to 10,000,000.
- A Certificate of Amendment to our Articles of Incorporation, which makes no material changes to our existing Articles of Incorporation other than incorporating the amendments described in the prior bullets.
- A change to our state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion in connection with which the Company will adopt a new certificate of incorporation and bylaws under the laws of the State of Delaware.
- The adoption of a 2017 Equity Incentive Plan.

Pursuant to the Plan, on June 23, 2017, we filed a Certificate of Amendment to our Articles of Incorporation with the Secretary of State of the State of Nevada to effect clauses (a), (b) and (c) above. A copy of the Certificate of Amendment to the Articles of Incorporation is annexed hereto as Exhibit 3.1 and is incorporated by reference herein. Pursuant to the Plan, on June 23, 2017, we filed Articles of Conversion with the Secretary of State of the State of Nevada for our Reincorporation. The Articles of Conversion, including the Plan, are annexed hereto as Exhibit 3.2 and are incorporated by reference herein.

In connection with the Reincorporation and pursuant to the Plan, on June 28, 2017, the Secretary of State of the State of Delaware accepted the Company’s filing of a Certificate of Conversion and a Certificate of Incorporation. The Certificate of Conversion and Certificate of Incorporation are annexed hereto as Exhibits 3.3 and 3.4, respectively, and are incorporated by reference herein. In connection with the Reincorporation, the Company adopted new By-Laws, which are annexed hereto as Exhibit 3.5 and incorporated by reference herein.

### Recent Events

#### Merger with NeuroOne, Inc.

On July 20, 2017, we entered into the Merger Agreement with NeuroOne, Inc. and OSOK Acquisition Company to acquire NeuroOne, Inc. (the “Acquisition”). The transactions contemplated by the Merger Agreement were consummated on July 20, 2017 (the “Closing”) and, pursuant to the terms of the Merger Agreement, (i) all outstanding shares of common stock of NeuroOne, Inc., par value $0.0001 per share (the “NeuroOne Shares”) were exchanged for shares of our common stock, par value $0.001 per share (the “Company Shares”) based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share, resulting in us issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne, Inc. were replaced with options to purchase Company Shares based on the exchange ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 365,716 Company Shares for issuance upon the exercise of options, (iii) all warrants of NeuroOne, Inc. were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible promissory notes of NeuroOne, Inc. The NeuroOne options had been issued pursuant to the NeuroOne, Inc. 2016 Equity Incentive Plan. Pursuant to the Merger Agreement, the Company assumed the 2016 Plan upon the Closing.

Pursuant to the Acquisition, we acquired 100% of NeuroOne, Inc. in exchange for the issuance of Company Shares and NeuroOne, Inc. became our wholly-owned subsidiary. Also at the Closing, Mr. Samad tendered for cancellation 3,500,000 Company Shares held by him as part of the conditions to Closing. A copy of the Merger Agreement is annexed hereto as Exhibit 2.1 and is incorporated by reference herein.

In connection with the Acquisition, Amer Samad, formerly our sole director and officer, appointed the person designated by NeuroOne, Inc. to our board of directors and resigned from all officer positions. Our newly constituted board of directors immediately appointed the officers designated by NeuroOne, Inc. On August 4, 2017, Mr. Samad resigned as a director and three new members of the board of directors were appointed.

Please see our Current Report on Form 8-K filed with the SEC on July 20, 2017 (the “Acquisition 8-K”) for additional information regarding the Acquisition. In connection with the filing of this Quarterly Report on Form 10-Q, we are filing Amendment No. 1 on Form 8-K/A (the “Second Quarter 8-K/A”) to amend the Acquisition 8-K in order to (i) provide financial information of NeuroOne, Inc. for its fiscal quarter ended June 30, 2017, pro forma financial information for us as of June 30, 2017 and related updated disclosures, in each case, in accordance with the guidance set forth under Topic 12 of the Division of Corporation Finance Financial Reporting Manual so that there is no lapse in periodic reporting for the quarter ended June 30, 2017 and (ii) to correct an administrative error concerning the number of shares of common stock held directly by one of the holders of over 5% of our common stock as of the Closing.

### Critical Accounting Policies

The following discussion as well as disclosures included elsewhere in this Form 10-Q are based upon our unaudited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingencies. We continually evaluate the accounting policies and estimates used to prepare the financial statements. We base our estimates on historical experiences and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by us.

### Results of Operations

During the three and six months ended June 30, 2017, we earned revenues of $0. We had general and administrative expenses of $23,621 and $32,375 during the three and six months ended June 30, 2017, respectively, and a gain from discontinued operations of zero and $17,530 for the three and six months ended June 30, 2017, respectively. The gain from discontinued operations was attributed to the settlement of net liabilities from discontinued operations. As a result, we had a net loss of $23,621 and $14,845 for the three and six months ended June 30, 2017, respectively.

By comparison, during the three and six months ended June 30, 2016, we earned revenues of $0. We had general and administrative expenses of $14,108 and $18,493 during the three and six months ended June 30, 2016, respectively, and a loss from discontinued operation during the three and six month periods ended June 30, 2016 of $10,591 and $15,164, respectively. As a result, we had a net loss of $24,699 and $33,657 for the three and six months ended June 30, 2016, respectively.

The $9,513 increase in loss from operations for the three months ended June 30, 2017 compared to the three months ended June 30, 2016 was due to costs incurred in connection with the Acquisition primarily for professional fees, which consist of fees paid for legal, accounting, and auditing services.

The $13,882 increase in loss from operations for the six months ended June 30, 2017 compared to the six months ended June 30, 2016 was primarily the result of an increase in general and administrative expenses of $13,882 primarily from professional fees incurred in connection with the Acquisition.

### Liquidity and Capital Resources

At June 30, 2017 and December 31, 2016 we had a cash balance of $0.

The accompanying condensed financial statements have been prepared assuming that we will continue as a going concern. As shown in the accompanying financial statements, we have incurred losses of $23,621 and $24,699 for the three months ended June 30, 2017 and 2016, respectively, and $14,845 and $33,657 for the six months ended June 30, 2017 and 2016, respectively. Our accumulated retained deficit was $179,145 as of June 30, 2017. We have a working capital deficiency which raises substantial doubt about our ability to continue as a going concern.

After completion of the Acquisition on July 20, 2017, we will need to secure additional funding in August 2017. We plan to complete an equity financing in the third quarter of 2017. We may obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan.

Our continuation as a going concern is dependent upon our ability to ultimately attain profitable operations, generate sufficient cash flow to meet our obligations, and obtain additional financing as may be required. Our auditors have included a “going concern” qualification in their auditors’ report dated April 17, 2017. Such a “going concern” qualification may make it more difficult for us to raise funds when needed. The outcome of this uncertainty cannot be assured.

See the Acquisition 8-K and the Second Quarter 8-K/A for the discussion our liquidity and capital resources taking into account the Acquisition and the business of NeuroOne, Inc.

The accompanying condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The following table summarizes our cash flows for the periods indicated:

*(in thousands)*

|  | For the Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(11,572) | $(8,210) |
| Net cash provided by (used in) investing activities | — | — |
| Net cash provided by financing activities | 11,572 | 8,210 |
| Net increase (decrease) in cash | $— | $— |

#### Operating Activities

During the six months ended June 30, 2017, we used $11,572 of cash in operating activities compared to $8,210 during the six months ended June 30, 2016.

During the six months ended June 30, 2017 we incurred a loss of $14,845 which included a non-cash gain of $17,530 for discontinued operations, and was partially offset for cash flow purposes as we increased our balance of accounts payable and accrued liabilities by $20,803. By comparison, during the six months ended June 30, 2016, we incurred a loss of $33,657 which was partially offset for cash flow purposes by an increase in our balance of equity from discontinued operations by $15,617, an increase in our balance of accounts payable and accrued liabilities by $10,283 as well as an increase in our balance of liabilities from discontinued operations of $1,986 offset by an increase in in our balance of assets from discontinued operations of $2,439.

#### Investing Activities

During the six month periods ended June 30, 2017 and 2016, we did not pursue any investing activities.

#### Financing Activities

During the six months ended June 30, 2017, we received $11,572 by way of advances from a related party. By comparison, we received $8,210 from advances from a related party during the six months ended June 30, 2016.

### Recently Issued Accounting Standards

We do not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying financial statements.

### Off Balance Sheet Arrangements

None.

## Controls and procedures

As filed, 1,496 characters.

During the three months ended June 30, 2017, there were no changes in our internal controls over financial reporting (as defined in Rule 13a- 15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our chief executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of June 30, 2017. Based on this evaluation, our chief executive officer and principal financial officer have concluded such controls and procedures to be ineffective as of June 30, 2017 to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms and to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

## Risk factors

As filed, 710 characters.

Factors that could cause our actual results to differ materially from those in this Quarterly Report on Form 10-Q are any of the risks described in our Acquisition 8-K. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Acquisition 8-K. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

Filed Aug 14, 2017.
Source: SEC EDGAR, the filing index for accession 0001144204-17-043228. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.
